What does this research mean for the field?

Serum magnesium is an inadequate biomarker for clinical trials because it is homeostatically defended and poorly reflects tissue levels, causing trials to be statistically underpowered and masking true clinical benefits. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

To evaluate why standard serum magnesium testing fails to detect tissue deficiency or track oral supplementation efficacy, and to model compartment-specific biomarker kinetics.

August 29, 2026Journal of the American Nutrition Association

Why Serum Magnesium Fails: A Narrative Review of Magnesium Biochemistry, Compartmental Exchange, and Endpoint Selection for Supplementation Trials

View Full Paper

Ask AI

Bookmark

Authors

JCJagdish ChandaranaGovernment Medical College KBKinjal ButaniGovernment Medical College

Discussion

Member takes

Implication

Narrative review reveals serum magnesium fails to reflect tissue repletion during supplementation, indicating clinical trials require compartmental biomarkers like erythrocyte magnesium.

Key Points

To evaluate why standard serum magnesium testing fails to detect tissue deficiency or track oral supplementation efficacy, and to model compartment-specific biomarker kinetics.
Conducted a narrative review examining magnesium biochemistry, physiological multi-timescale compartmental exchange models, and biochemical trial endpoints.
Appraised serum, erythrocyte, ionized, urinary, and loading-test measurements against biological variation data across hypertension, diabetes, insomnia, cramping, and migraine prophylaxis.
Serum magnesium accounts for less than 1% of total body magnesium and is homeostatically defended by renal reabsorption and bone exchange, allowing tissue depletion to persist within normal reference intervals.
Biological variation establishes a reference change value of approximately 12% for serum magnesium and a critical difference of approximately 22% for erythrocyte magnesium, which equals or exceeds typical supplementation changes and renders trials underpowered.
Clinical improvements across five therapeutic areas occur without commensurate changes in serum levels, establishing the need for context-dependent measurement hierarchies and standardized erythrocyte reference intervals.

Cite This Study

Chandarana et al. (2026) studied this question.

synapsesocial.com/papers/6a9298d38e5d7d1fc0c10a07 https://doi.org/10.1080/27697061.2026.2719468

View Full Paper

Ask AI

Bookmark

August 29, 2026Journal of the American Nutrition Association

Why Serum Magnesium Fails: A Narrative Review of Magnesium Biochemistry, Compartmental Exchange, and Endpoint Selection for Supplementation Trials

View Full Paper

Ask AI

Bookmark

Authors

JCJagdish ChandaranaGovernment Medical College KBKinjal ButaniGovernment Medical College

Discussion

Member takes

Implication

Narrative review reveals serum magnesium fails to reflect tissue repletion during supplementation, indicating clinical trials require compartmental biomarkers like erythrocyte magnesium.

Key Points

To evaluate why standard serum magnesium testing fails to detect tissue deficiency or track oral supplementation efficacy, and to model compartment-specific biomarker kinetics.
Conducted a narrative review examining magnesium biochemistry, physiological multi-timescale compartmental exchange models, and biochemical trial endpoints.
Appraised serum, erythrocyte, ionized, urinary, and loading-test measurements against biological variation data across hypertension, diabetes, insomnia, cramping, and migraine prophylaxis.
Serum magnesium accounts for less than 1% of total body magnesium and is homeostatically defended by renal reabsorption and bone exchange, allowing tissue depletion to persist within normal reference intervals.
Biological variation establishes a reference change value of approximately 12% for serum magnesium and a critical difference of approximately 22% for erythrocyte magnesium, which equals or exceeds typical supplementation changes and renders trials underpowered.
Clinical improvements across five therapeutic areas occur without commensurate changes in serum levels, establishing the need for context-dependent measurement hierarchies and standardized erythrocyte reference intervals.

Cite This Study

Chandarana et al. (2026) studied this question.

synapsesocial.com/papers/6a9298d38e5d7d1fc0c10a07 https://doi.org/10.1080/27697061.2026.2719468

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark